Abstract:BackgroundIn haemato-oncologic patients bacteremia is frequent increasing mortality rates, therefore surveillance and close follow up is essential to optimize treatment. The use of invasive devices used frequently in this population increases the incidence of infections by gram-positive microorganisms (currently gram-negative bacilli have been added). Therefore, we propose the characterization the microorganisms to identify the epidemiologic conditions, and the areas of improvement to establish improvement care strategies for this population.MethodsWe conducted a retrospective study at the haemato-oncologic diseases service at the National Medical Center "20 de Noviembre". Prevalence of bacteremia in pediatric patients with cancer and neutropenia in Mexican population, which ranges from 8% to 36%, assuming that our results could be similar to higher percentage, employing a proportion formula with a study population of 65 patients.ResultsIt was demonstrated in our population studied that in all cases of bacteremia, patients were in depth neutropenia at diagnosis. The most prevalence phase of chemotherapy was Induction phase (69.2%), with Total XV ST Jude protocol. The clinical data revealed the following frequencies in 100% of the patients: Fever (92%), Tachycardia (72%), Shivering and piloerection (65%), Elevated acute-phase reactants PCT (51%), CPR (32%), and Tachypnea (28%). Cases of Central Line-associated Bloodstream Infection (CLABSI) was reported in 86.2%, affecting individuals with vascular devices. The predominant microbiological isolate in our patients was Escherichia coli ESBL (31%), followed by Klebsiella pneumoniae (18%), and Pseudomonas aeruginosa (13.8%), Staphylococcus epidermidis (11%). Other bacteria were identified at even lower frequencies, such as Stenotrophomonas maltophilia (5%), Klebsiella oxytoca (5%), Staphylococcus aureus (3%), Serratia marcescens (3%), Enterococcus faecalis (3%), and Enterobacter cloacae (3%). The least observed in our population was the identification of Acinetobacter bauman nii (2%). The different outcomes recorded in our sample were highly consistent, with a resolution rate of infection in 97% of cases and 3% of cases resulting in death attributable to bacteremia (Table 1).ConclusionThe low mortality found in this study may be due to the early initiation of empirical antibiotic treatment in "golden hour", a protocol carried out in our Center, as well as the identification of severity scales.Table 1 General characteristics of children with bacteremia and malignant neoplasiaTotaln = 65 Neoplasm TypepHematologicaln = 48 Solidn = 17 Age, years8.13 ± 3.77.83 ± 3.79.00 ± 3.770.276Gender Female Male41 (63%)24 (37%)34 (71%)14 (29%)7 (41%)10 (69%)0.059Invasive Devices Without invasive devices Vascular catheter Urinary catheter Endotrachealtube Others2 (3%)63 (97%)9 (14%)8 (12%)1 (2%)2 (4%)46 (96%)8 (17%)5 (10%)1 (2%)017 (100%)2 (12%)2 (12%)00.96990.96990.928111 Depth Neutropenia Days65 (100%)9 (6 – 12)48 (100%)10 (6.5 - 11.5)17 (100%)7 (5.2 – 13.5)NA: 0.4931 * Microbiológical isolation Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa S. Epidermidis S. Maltophilia Klebsiella oxytoca Staphyloccocus Aureus Serratia marcescens Enterococcus faecalis Enterobacter cloacae Staphyloccocus hominis Acinetobacter baumannii 21 (32%)12 (18%)9 (13.8%)7 (11%)3 (5%)3 (5%)2 (3%)2 (3%)2 (3%)2 (3%)1 (2%)1 (2%)18 (38%)10(21%)8 (17%)5 (10%)2 (4%)1 (2%)1 (2%)2 (4%)2 (4%)2 (4%)1 (2%)1 (2%)3 (18%)2 (12%)1 (6%)2 (12%)1 (6%)2 (12%)1 (2%)00000NAHospital stay (days)25(17.5 – 29.5)26(17.5 – 29.5)24(17.2 – 29.5)0.9107 * Outcome Infection resolved Attributable death63 (97%)2 (3%)46 (96%)2 (4%)17 (100%)00.9699

Trends in infections in children with malignant disease in 2000: comparison of data of 1980/81

Trends in Mortality from Infection among Patients with Hematologic Malignancies: Differences According to Hematologic Malignancy Subtype.

Clinical Features of Bloodstream Infection in Children with Haematological Malignancies

Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment

Profile Of Infectious Complications in Pediatric Oncology Patients: Experience from Tertiary Referral Hospital in Low and Middle-Income Country

Prevalence, Epidemiology, Etiology, and Sensitivity of Invasive Bacterial Infections in Pediatric Patients Undergoing Oncological Treatment: A Multicenter Nationwide Study.

Infections Deaths in Acute Lymphoblastic Leukemia More Frequent in High Risk Leukemia

Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

Microbiologically Documented Bloodstream Infection in Children with Malignancies: A Single-center Experience.

Clinical Characteristics and Risk Factors for Bloodstream Infections in Children with Cancer: A Report from a Pediatric Hematology Oncology Unit

Infections in Children with Acute Lymphoblastic Leukemia

Bacteremias in Hemato-Oncological Pediatric Patients: Clinical and Microbiological Characteristics

Pathogen Investigation on Infections in Children with Neoplastic Disease

Infections During Induction Therapy of Protocol CCLG-2008 in Childhood Acute Lymphoblastic Leukemia: A Single-center Experience with 256 Cases in China

Nosocomial Infection in Children with Malignancies During Neutropenia Stage: A Clinical Investigation

No Impact of Dietary Restrictions on the Risk for Infection in Pediatric Patients With Cancer: A Monocenter Analysis

[Causes of Deaths of Children with Malignant Tumors During Hospitalization in a Single Center].

Evaluation of Th1/Th2 cytokines as a rapid diagnostic tool for severe infection in paediatric haematology/oncology patients by the use of cytometric bead array technology.

Increased T regulatory cells and decreased Th1 pro-inflammatory cytokines correlate with culture-positive infection in febrile neutropenia childhood oncology patients

Comparison of the Diagnostic Power Between Cytokine Pattern and Procalcitonin for Predicting Infection in Pediatric Hematology/Oncology Patients

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012